- ROUNDTABLE: Pharmacy’s future in sync with technology
- Study: Daily aspirin use may reduce risk of ovarian cancer by 20%
- CVS Caremark to stop selling tobacco in all store locations
- Q&A: Genetic profiling with Dr. Anita Goel of Nanobiosym
- EXPERT BLOG: Provider status for pharmacists — one way or another
THOUSAND OAKS, Calif. — A drug made by Amgen was able to delay certain bone problems in patients with advanced breast cancer better than a competing drug, according to study results presented at the 33rd annual San Antonio Breast Cancer Symposium.
Amgen said Xgeva (denosumab) was able to delay weakness and fracturing resulting from the cancer spreading to the bones five months longer than Novartis’ Zometa (zoledronic acid).
The Food and Drug Administration approved Xgeva on Nov. 18.